Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features

The Fox Investigation of New Biomarker Discovery

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalMovement Disorders
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2018

Bibliographical note

Funding Information:
Acknowledgments: BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson’s Research with support from the National Institute for Neurological Disorders and Stroke. Data used in the preparation of this article were obtained from the Fox Investigation for New Discovery of Biomarkers (“BioFIND”) database (http://biofind.loni.usc. edu/). For up-to-date information on the study, visit www.michaeljfox. org/biofind. We appreciate the assistance of Dr. Thong Ma for preparation of the figures.

Funding Information:
*Corresponding author: Dr. Jennifer G. Goldman, Rush University Medical Center, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612; Jennifer_G_Goldman@rush.edu Funding agencies: BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson’s Research with support from the National Institute for Neurological Disorders and Stroke.

Keywords

  • alpha-synuclein
  • amyloid
  • cerebrospinal fluid
  • postural instability gait difficulty
  • tau

Fingerprint Dive into the research topics of 'Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features'. Together they form a unique fingerprint.

Cite this